|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0006142,
umls-concept:C0008976,
umls-concept:C0045093,
umls-concept:C0086960,
umls-concept:C0144576,
umls-concept:C0205179,
umls-concept:C0205390,
umls-concept:C0282564,
umls-concept:C0439590,
umls-concept:C0574032,
umls-concept:C0585332,
umls-concept:C1516213
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2011-2-22
|
|
pubmed:abstractText |
Paclitaxel (PACL) plus gemcitabine (GEM) is an effective regimen for advanced breast cancer patients pretreated with anthracyclines. A prolonged GEM infusion at a fixed dose rate (FDR) of 10 mg/m²/min produces higher levels of intracellular active metabolites of GEM when compared with a standard 30-min infusion. In the present phase I/II trial, we investigated the association of FDR GEM plus PACL.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1432-0843
|
|
pubmed:author |
pubmed-author:BeplerGeroldG,
pubmed-author:CognettiFrancescoF,
pubmed-author:ContiFrancescaF,
pubmed-author:Di LauroLuigiL,
pubmed-author:FabiAlessandraA,
pubmed-author:GiannarelliDianaD,
pubmed-author:LopezMassimoM,
pubmed-author:MetroGiulioG,
pubmed-author:SergiDomenicoD,
pubmed-author:TomaoFedericaF,
pubmed-author:ViciPatriziaP
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
67
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
687-93
|
|
pubmed:meshHeading |
pubmed-meshheading:20512334-Adult,
pubmed-meshheading:20512334-Aged,
pubmed-meshheading:20512334-Anthracyclines,
pubmed-meshheading:20512334-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:20512334-BRCA1 Protein,
pubmed-meshheading:20512334-Breast Neoplasms,
pubmed-meshheading:20512334-Deoxycytidine,
pubmed-meshheading:20512334-Disease-Free Survival,
pubmed-meshheading:20512334-Drug Administration Schedule,
pubmed-meshheading:20512334-Female,
pubmed-meshheading:20512334-Humans,
pubmed-meshheading:20512334-Middle Aged,
pubmed-meshheading:20512334-Neoplasm Recurrence, Local,
pubmed-meshheading:20512334-Paclitaxel,
pubmed-meshheading:20512334-Survival,
pubmed-meshheading:20512334-Time Factors,
pubmed-meshheading:20512334-Treatment Outcome,
pubmed-meshheading:20512334-Tumor Suppressor Proteins,
pubmed-meshheading:20512334-Young Adult
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Phase I-II trial of prolonged gemcitabine infusion plus paclitaxel as a biweekly schedule for advanced breast cancer patients pretreated with anthracyclines.
|
|
pubmed:affiliation |
Department of Medical Oncology, Regina Elena Cancer Institute, Rome, Italy. pvici@ifo.it
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Clinical Trial, Phase II,
Clinical Trial, Phase I
|
